These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34869744)

  • 1. Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance.
    Razmara AM; Judge SJ; Gingrich AA; Cruz SM; Culp WTN; Kent MS; Rebhun RB; Canter RJ
    Front Vet Sci; 2021; 8():771737. PubMed ID: 34869744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
    Cascio MJ; Whitley EM; Sahay B; Cortes-Hinojosa G; Chang LJ; Cowart J; Salute M; Sayour E; Dark M; Sandoval Z; Mitchell DA; Milner RJ
    Vet Immunol Immunopathol; 2021 Feb; 232():110169. PubMed ID: 33387703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.
    Kisseberth WC; Lee DA
    Front Vet Sci; 2021; 8():672361. PubMed ID: 34164452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved characterization and translation of NK cells for canine immunotherapy.
    Razmara AM; Gingrich AA; Toedebusch CM; Rebhun RB; Murphy WJ; Kent MS; Canter RJ
    Front Vet Sci; 2024; 11():1336158. PubMed ID: 38379924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
    Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
    Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
    Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
    Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
    J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
    Yang H; Zhao L; Zhang Y; Li FF
    Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
    Mason NJ
    Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
    Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large Scale Comparative Deconvolution Analysis of the Canine and Human Osteosarcoma Tumor Microenvironment Uncovers Conserved Clinically Relevant Subtypes.
    Patkar S; Mannheimer J; Harmon S; Mazcko C; Choyke P; Brown GT; Turkbey B; LeBlanc A; Beck J
    bioRxiv; 2023 Sep; ():. PubMed ID: 37808704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
    Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
    PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans.
    Mannheimer JD; Tawa G; Gerhold D; Braisted J; Sayers CM; McEachron TA; Meltzer P; Mazcko C; Beck JA; LeBlanc AK
    Commun Biol; 2023 Aug; 6(1):856. PubMed ID: 37591946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma.
    Withers SS; York D; Choi JW; Woolard KD; Laufer-Amorim R; Sparger EE; Burton JH; McSorley SJ; Monjazeb AM; Murphy WJ; Canter RJ; Rebhun RB
    Vet Comp Oncol; 2019 Sep; 17(3):242-252. PubMed ID: 30684301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.